scholarly journals CDK4 Gene Amplification

2020 ◽  
Author(s):  
Keyword(s):  
Gene Amplification ◽  
Cdk4 Gene

Gnathic giant-cell-rich conventional osteosarcoma with MDM2 and CDK4 gene amplification

2017 ◽  
Vol 70 (7) ◽  
pp. 1171-1173 ◽  
Author(s):  
Katsutoshi Hirose ◽  
Masaya Okura ◽  
Sunao Sato ◽  
Shumei Murakami ◽  
Jyun-Ichiro Ikeda ◽  
...  
Keyword(s):  
Giant Cell ◽  
Gene Amplification ◽  
Conventional Osteosarcoma ◽  
Cdk4 Gene

Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P16ink4 homozygous deletions and CDK4 gene amplifications

1996 ◽  
Vol 84 (6) ◽  
pp. 1020-1023 ◽  
Author(s):  
Joseph Petronio ◽  
Ju He ◽  
Daniel Fults ◽  
Carolyn Pedone ◽  
C. David James ◽  
...  
Keyword(s):  
Gene Amplification ◽  
Gene Encoding ◽  
Primary Tumors ◽  
Content Type ◽  
Primitive Neuroectodermal Tumors ◽  
Malignant Astrocytomas ◽  
Neuroectodermal Tumors ◽  
Cdk4 Gene ◽  
Homozygous Deletions ◽  
Gene Alterations

✓ Alterations in P16ink4 or in the gene encoding one of its ligands, cyclin-dependent kinase 4 (CDK4), have been reported in human glioma cell lines and primary tumors but not in primitive neuroectodermal tumors (PNETs), the most common malignant brain tumor of childhood. In this study the authors have examined DNA from 20 primary PNETs in children and from 20 malignant astrocytomas to assess the frequency of P16ink4 and CDK4 gene alterations associated with each type of tumor. Southern hybridization analysis revealed homozygous P16ink4 deletions in one (5%) of 20 PNETs and in seven (35%) of 20 malignant astrocytomas. The CDK4 gene amplification was evident in two additional astrocytomas, but not in any of the PNETs. In total, nine astrocytomas (45%) exhibited homozygous P16ink4 deletion or CDK4 gene amplification, but only one PNET (5%) demonstrated either gene alteration. These results indicate that the incidence of P16ink4 and CDK4 gene alterations in these two groups of tumors is different and suggest distinct pathogenetic etiologies may be associated with each neoplasm.

MDM2/CDK4 gene amplification in large/deep-seated ‘lipomas’: incidence, predictors and clinical significance

Pathology ◽  
2016 ◽  
Vol 48 (3) ◽  
pp. 203-209 ◽  
Author(s):  
Daniel D. Wong ◽  
Irene C. Low ◽  
Joanne Peverall ◽  
Peter D. Robbins ◽  
Dominic V. Spagnolo ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Gene Amplification ◽  
Cdk4 Gene

Reevaluation of gene amplification in medulloblastomas

2004 ◽  
Vol 216 (03) ◽  
Author(s):  
T Lenschen ◽  
J Mühlisch ◽  
H Jürgens ◽  
C Plass ◽  
D Smiraglia ◽  
...  
Keyword(s):  
Gene Amplification

HER-2 gene amplification in pancreatic cancer

2004 ◽  
Vol 42 (05) ◽  
Author(s):  
K Borka ◽  
A Kiss ◽  
A Tőkés ◽  
P Kaliszky ◽  
P Kupcsulik ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Amplification ◽  
Her 2

Blocking of CDK4 Gene Expression by Antisense Oligos Induce Apoptosis and Decreases the Proliferation of A549 Cells

2012 ◽  
Vol 2 (8) ◽  
pp. 51-53
Author(s):  
Babu R L Babu R L ◽  
◽  
Vijayalakshmi E Vijayalakshmi E ◽  
Naveen Kumar M Naveen Kumar M ◽  
Rajeshwari H. Patil ◽  
...  
Keyword(s):  
Gene Expression ◽  
A549 Cells ◽  
Cdk4 Gene ◽  
Antisense Oligos

A PILOT STUDY OF HER-2/NEU GENE AMPLIFICATION ASSESSED BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GASTRIC CANCER

2014 ◽  
pp. 15-20
Author(s):  
Van Huy Tran ◽  
Thi Minh Thi Ha ◽  
Trung Nghia Van ◽  
Viet Nhan Nguyen ◽  
Phan Tuong Quynh Le ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Cancer Patients ◽  
Gene Amplification ◽  
Cancer Tissue ◽  
Tissue Samples ◽  
Her 2 ◽  
Gastric Cancer Patients

Background: HER-2/neu is a predictive biomarker for treatment of gastric cancer using trastuzumab in combination with chemotherapy. This study aimed to evaluate the status of HER-2/neu gene amplification using fluorescence in situ hybridization (FISH) in gastric cancer. Patients and methods: thirty six gastric cancer patients were assessed HER-2/neu gene amplification by FISH using PathVysionTM HER-2 DNA Probe kit (including HER-2/neu probe and CEP-17 probe) with biopsy and surgical specimens. Results: The HER-2/neu gene amplification was observed in three cases (8.3%), the HER-2/neu gene amplification rate in Lauren’s intestinal-type and diffuse-type were 11.8% and 5.2%, respectively. Conclusion: We applied successfully FISH technique with gastric cancer tissue samples. This technique could be performed as routine test in gastric cancer in order to select patients that benefit from trastuzumab in combination with chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document